http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2474558-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a4d9078ec6121bcfa0adc00a078ee16
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2318-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1228
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6835
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1214
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6829
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1217
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
filingDate 2010-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c9edb48cd4f8daf7e99377473f3cb905
publicationDate 2012-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber EP-2474558-A1
titleOfInvention New antibiotic containing simulacrum antibody, preparation method and application thereof
abstract The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic comprising a mimetic antibody, its preparation methods and uses thereof. The novel antibiotic comprising comprising an antibody mimetic and a colicin,or comprising an antibody mimetic and a channel-forming domain of a colicin, the antibody mimetic covalently bonded to the carboxyl end of the polypeptide of the colicin or the channel-forming domain of the colicin, wherein the colicin is selected from a group consisting of colicin E1, Ia, Ib, A, B, N; wherein said antibody mimetic being yielded by fusing two complementarity determining regions (CDRs), V H CDR 1 ) and V L CDR through a cognate framework region (V H FR 2 ) of an immunoglobulin; wherein the immunoglobulin specifically recognizes bacterium porins. Its antibacterial ability is a thousandfold powerful than normal antibiotics. Due to its unique action mechanism, drug resistance resulted in mutation can hardly be acquired by pathogenic bacteria. And the antibiotic will not hurt normal human cells when it kills pathogenic bacteria. Therefore, it can be used for manufacturing antibacterial medicament of killing Diplococcus intracellularis, vancomycin-resistant enterococci, Methicillin-resistant Staphylococcus aureus, or multidrug resistant Pseudomonas aeruginosa.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10071358-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9611299-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014349880-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2792749-A4
priorityDate 2009-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007083175-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5484131
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127998401
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14969
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5651
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395499
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395500
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395375
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226422792
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129432415
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16051958
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395424
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226422791
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57134040
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395423
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128850235
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5481173
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395685
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405795
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395422
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54197
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6196
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16051955
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19649
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID149096
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6249
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395922

Total number of triples: 59.